Xintela and EQGen Biomedical sign collaboration and license agreement for veterinarian stem cell products

Xintela and EQGen Biomedical Inc. (“EQGen”) have signed a collaboration and license agreement for the development of Xintela’s equine stem cell product EQSTEM® and other animal stem cell products. EQGen gets global rights to Xintela’s stem cell technology for the treatment of veterinary musculoskeletal indications. Xintela and EQGen Biomedical will collaborate on product and process development as well as regulatory, clinical and commercial development of EQSTEM, initially for the treatment of joint diseases in horses.